Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Shanghai Xuerong Biotechnology financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.


¥2 B

FY, 2021

CreditSafe Score

Score changed on Apr 16, 2024
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn more

Financial Statements

CNYFY, 2018FY, 2019FY, 2020FY, 2021
Cost of goods sold1.6B1.5B1.7B2.0B
Gross profit247.4M414.5M466.2M91.9M
Gross profit margin, %14.0%21.5%21.5%4.6%
Operating expense total(134.8M)(145.3M)59.1M(99.9M)
Depreciation and amortization266.2M283.6M128.6M407.9M
EBITDA margin, %21.6%29.0%18.8%9.5%
EBIT margin, %12.2%14.6%13.0%-13.7%
Interest income4.4M4.6M4.9M6.5M
Interest expense78.8M78.7M71.7M77.1M
Pre tax profit141.9M208.1M221.8M(353.0M)
Income tax expense17.1M(953.0K)(3.2M)(4.5M)
Net Income124.8M209.0M225.1M(348.5M)

Footer menu